AstraZeneca sets up new division for vaccines and antibody therapies

Move shows company sees future for Covid-19 vaccine beyond pandemic, says analyst

Ascendis activist shareholders get board representation

Move at health and wellness group seen as victory for ordinary investors

Dis-Chem shares surge on expansion, high profits

Pharmaceutical chain grows footprint and sets up new lines of business

Aspen proposes a special economic zone at its Gqeberha site

The pharmaceutical production hub has scope to spawn an ecosystem of suppliers, says Ebrahim Patel

Mark Sardi steps down as Ascendis Health CEO

He is credited with reducing the healthcare firm’s debt by R7.5bn by swapping debt for assets and increasing total normalised earnings

Aspen sells portfolio of six drugs for R1.8bn

Group is streamlining SA portfolio and will use sale proceeds to address debt pile

Netcare says profit is steadily improving despite the third wave

Hospital group has got better at managing the influx of Covid-19 patients, even as each wave has been more severe

Pfizer study shows booster jab restores efficacy to 95.6% against Covid-19

The trial results show boosters can play an important role in pandemic containment, says  BioNTech CEO

Financially healthy J&J wants to negotiate settlement under bankruptcy rules

The company created a new corporation responsible for paying all baby-powder claims, then put that unit into bankruptcy where it will seek a temporary halt to ...

Mediclinic surges as it jumps back to prepandemic revenue

Income rises more than 9%, hospital group encouraged by return of nonelective operations

CureVac pulls Covid-19 vaccine candidate to focus on work with GSK

Shares sink almost 14% as German biotech's shot becomes latest casualty in vaccine race

AstraZeneca says antibody shot cuts risk of severe Covid by 50%

Antibody cocktail reduced the risk of severe Covid-19 or death in patients, a study shows

AfroCentric to offer in-house Covid-19 jabs for larger companies

The Medscheme owner wants to make it easy for corporate employees to get vaccinated

Shareholders give nod to ‘new Ascendis’

In total, 98.53% of Ascendis shareholders have approved restructuring aimed at solving its unsustainable debt structure, and which may see it delist

Medical aid schemes blame laws for barring cheaper health cover

Prescribed minimum benefits said to rule out provision of more affordable options to lower-income consumers

Ascendis could be poised for ‘strategic pivot’ to go private

Shareholders are expected to approve a restructuring plan that will save the group from business rescue, but it won’t end there

Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.